Authors

Ticiana A. Leal, MD, University of Wisconsin School of Medicine

Ticiana Leal, MD, University of Wisconsin-Madison

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

Tiffany A. Traina, MD

Latest:

Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

Latest:

Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Tiffany Traina, MD, Memorial Sloan Kettering Cancer Center

Latest:

Consequences of Chemotherapy-Induced Neutropenia

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

Tim F. Greten, MD

Latest:

Dr. Greten on the Tumor Microbiome and Antitumor Immunity in Liver Cancer

Tim F. Greten, MD, discusses the role of the gut microbiome in antitumor immunity in liver cancer.

Tim F. Greten, MD, National Cancer Institute

Tim G. Larson, MD

Latest:

Dr. Larson on Ongoing Trials in Colorectal Cancer

Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

Tim H.-M. Huang, PhD

Latest:

The Era of Interrogating Single Cells in Cancer Biopsy Is Now

Even in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.

Tim Iveson, MD, FACP

Latest:

Dr. Iveson on the IDEA Collaboration in CRC

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Tim Kruser, MD, Feinberg School of Medicine

Tim Turnham, PhD

Latest:

Tim Turnham on the Melanoma Research Foundation

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Timil Patel, MD

Latest:

Dr. Patel on Sequencing Therapy in Rectal Cancer

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

Timothy D. Shafman, MD

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Timothy F. Burns, MD, PhD

Latest:

Dr. Burns on the Evolving Use of ADCs in HER2-mutant NSCLC

Timothy Burns, MD, PhD, discusses the evolving use of antibody-drug conjugates in HER2-mutant non–small cell lung cancer.

Timothy Fenske, MD, MS

Latest:

Dr Fenske on the Omission of ASCT in Mantle Cell Lymphoma After First CR and uMRD

Timothy S. Fenske, MD, MS, discusses implications for data on the omission of auto-HCT in MCL after first CR and with undetectable MRD.

Timothy J. Daskivich, MD

Latest:

Dr. Daskivich Discusses Active Surveillance in Prostate Cancer

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses active surveillance for patients with prostate cancer.

Timothy J. Hobday, MD, Mayo Clinic College of Medicine

Timothy J. Whelan, BM, BCh

Latest:

Dr. Whelan Provides a MA.20 Trial Result Summary

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

Timothy M. Kuzel, MD, FACP

Latest:

Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.